Optimizing the start time of statin therapy for patients with diabetes

Medical Decision Making

Volumn 29, Issue 3, 2009, Pages 351-367

  Denton, Brian T ^a   Kurt, Murat ^b   Shah, Nilay D ^b   Bryant, Sandra C ^b   Smith, Steven A ^b  

^a North Carolina State University   (United States)

^b NONE

Author keywords

Diabetes; Markov decision process; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE; ARTICLE; CARDIOVASCULAR RISK; CHRONOTHERAPY; CONTROLLED STUDY; DRUG COST; EARLY INTERVENTION; GENDER; HYPERCHOLESTEROLEMIA; MEDICAL DECISION MAKING; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION MODEL; PROBABILITY; DRUG ADMINISTRATION; HUMAN; THEORETICAL MODEL;

DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MARKOV CHAINS; MODELS, THEORETICAL;

EID: 67649240453     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X08329462     Document Type: Article

References (41)

1. All About Diabetes. American Diabetes Association ; 2006. Available from: http://www.diabetes.org/about-diabetes.jsp
2. Turner RC The UK Prospective Diabetes Study: a review. Diabetes Care. 1998 ; 21: C35-8.
3. Davis TME, Millns H., Stratton IM, Holman RR, Turner RC Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med. 1999 ; 159: 1097-1103. (Pubitemid 29230862)
4. Stevens RJ, Kothari V., Adler AI, Stratton IM, Holman RR The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci. 2001 ; 101: 671-9.
5. Anderson KA, Odel PM, Wilson PWF, Kannel WB Cardiovascular disease risk profiles. Am Heart J. 1991 ; 121: 293-8.
6. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care. 2003 ; 26: 3093-101.
7. Eddy DM, Schlessinger L. Validation of the Archimedes diabetes model. Diabetes Care. 2003 ; 26: 3102-110.
8. Snow V., Aronson MD, Hornbake ER, Mottur-Pilson C., Weiss KB Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2004 ; 140: 644-9.
9. Garg A. Statins for all patients with type 2 diabetes: not so soon. Lancet. 2004 ; 364: 641-2.
10. Hayward RA, Hofer TP, Vijan S. Lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006 ; 145: 520-30.
11. Ko DT, Newman AM, Lee DS, Austin PC, Donovan LR, Tu JV Underutilization of effective treatment in diabetic patients admitted with acute myocardial infarction. J Am Coll Cardiol. 2004 ; 43: 405A - 6A.
12. Smith MA, Cox ED, Bartell JM Overprescribing of lipid lowering agents. Qual Safety Health Care. 2006 ; 15: 251-7.
13. Abookire SA, Karson AS, Fiskio J., Bates DW Use and monitoring of ''statin'' lipid-lowering drugs compared with guidelines. Arch Intern Med. 2001 ; 161: 53-8.
14. Health I. Press release: top 10 therapeutic classes by U.S. sales. IMS ; 2006. Available from: http://imshealth.com/ims/portal/front/articleC/0,2777, 6599-80408854-80411855,00.html
15. Schaefer AJ, Bailey MD, Shechter SM, Roberts MS Modeling medical treatment using Markov decision processes. In: Brandeau M, Sainfort F, Pierskalla W, eds. Handbook of Operations Re-search/Management Science Applications in Health Care. New York: Kluwer ; 2004. p 597-616.
16. Puterman ML Markov Decision Processes: Discrete Stochastic Dynamic Programming. New York: Wiley-Interscience ; 1994.
17. Gorman CA, Zimmerman BR, Smith SA, et al. DEMS: a second generation diabetes electronic management system. Comput Methods Programs Biomed. 2000 ; 62: 127-40.
18. National Center for Health Statistics. National Vital Statistics Reports. Hyattsville, MD: National Center for Health Statistics ; 2005.
19. Hebert PR, Gaziano JM, Chan KS, Hennekens CH Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA. 1997 ; 278: 313-21.
20. Maron DJ, Fazio S., Linton MF Current perspectives on statins. Circulation. 2000 ; 101: 207-13.
21. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham Study. Am Heart J. 2000 ; 139: 272-81.
22. Kothari V., Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke. 2002 ; 33: 1776-81.
23. Centers for Disease Control and Prevention (CDC). Advance Data from Vital and Health Statistics. Available from: http://www.cdc.gov/nchs/data/ad/ad347. pdf
24. Thom T., Haase N., Rosamond W., et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006 ; 113: E85-151.
25. Russell MW, Huse DM, Drowns S., Hamel EC, Hartz SC Direct medical costs of coronary artery disease in the United States. Am J Cardiol. 1998 ; 81: 1110-5.
26. Red Book: 2006 Edition. Ann Arbor, MI: Thomson Healthcare ; 2006.
27. Clarke P., Gray A., Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002 ; 22: 340-9.
28. Tsevat J., Goldman L., Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial-infarction. Med Decis Making. 1993 ; 13: 161-5.
29. Tengs TO, Yu M., Luistro E. Health-related quality of life after stroke: a comprehensive review. Stroke. 2001 ; 32: 964-71.
30. Tengs TO, Lin TH A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics. 2003 ; 21: 191-200. (Pubitemid 36286663)
31. Gage BF, Cardinalli AB, Albers GW, Owens DK Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial-fibrillation. JAMA. 1995 ; 274: 1839-45.
32. Zgibor JC, Piatt GA, Ruppert K., Orchard TJ, Roberts MS Deficiencies of cardiovascular risk prediction models for type 1 diabetes. Diabetes Care. 2006 ; 29: 1860-5.
33. Poynter JN, Gruber SB, Higgins PDR. Statins and the risk of colorectal cancer. N Engl J Med. 2005 ; 1352: 2184-92.
34. Young-Xu Y., Chan KA, Liao JK, Ravid S., Blatt CM Long-term statin use and psychological well-being. J Am Coll Cardiol. 2003 ; 42: 690-7.
35. Guyton JR Benefit versus risk in statin treatment. Am J Cardiol. 2006 ; 97: 95C - 7C.
36. Wang PS, Solomon DH, Mogun H., Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 2000 ; 283: 3211-6.
37. Kashani A., Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006 ; 114: 2788-97.
38. Jick H., Zornberg GL, Jick SS, Seshadri S., Drachman DA Statins and the risk of dementia. Lancet. 2000 ; 356: 1627-31.
39. Jackevicius CA, Mamdami M., Tu JV Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002 ; 288: 462-7.
40. Avorn J., Monette J., Lacour A., et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998 ; 279: 1458-62.
41. Benner JS, Glynn RJ, Mogun H., Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002 ; 288: 455-61.